Incretin therapies improve outcomes in heart failure with preserved ejection fraction and obesity.
- Current status
- EstablishedEvidence stable · Cardiovascular
- Why
- STEP-HFpEF (symptoms, 6-minute walk, CRP) and SUMMIT (CV death or worsening HF, HR 0.62) in people with BMI >= 30. Not applicable to HFpEF without obesity; SELECT HF subgroup analysis also positive.
- What would change it
- A trial in HFpEF with BMI < 30.
- Linked studies
- 3 · 3 supports
- Last updated
- Sep 13, 2026
The status is the collection's own judgment on its assessment scale, not a GRADE certainty rating and not medical advice.
01The evidence
The evidence, sorted by what it shows
Supports (3)
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and ObesityRandomized trial · 2025 · Study tier 2 · Different population · Benefit · Industry funded
SUMMIT: HR 0.62 for CV death or worsening HF; driven by HF events (CV death HR 1.58, few events).
- Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trialRandomized trial · 2024 · Study tier 2 · Different population · Benefit · Industry funded
SELECT prespecified HF analysis.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and ObesityRandomized, double-blind, placebo-controlled, parallel-group, multicentre, phase 3 trial; 52-week treatment period · 2023 · Study tier 2 · Different population · Benefit
STEP-HFpEF: KCCQ-CSS +7.8 points; weight -13.3%.
02History
How this assessment has changed
- EstablishedSep 13, 2026 · Evidence stable
initial curated status